Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study

被引：1

作者：

Okabe, Makoto ^{[1
]}

Yamamoto, Shuji ^{[1
]}

Shiokawa, Masahiro ^{[1
]}

Hisamatsu, Tadakazu ^{[1
,2
]}

Yamazaki, Hajime ^{[3
]}

Nakanishi, Risa ^{[1
]}

Hamada, Kensuke ^{[1
]}

Kitamoto, Hiroki ^{[1
]}

Kuwada, Takeshi ^{[1
]}

Uza, Norimitsu ^{[1
]}

Sakatani, Aki ^{[4
]}

Fujii, Toshimitsu ^{[5
]}

Ohno, Masashi ^{[6
]}

Matsuura, Minoru ^{[2
]}

Shibuya, Tomoyoshi ^{[7
]}

Ohmiya, Naoki ^{[8
]}

Ooi, Makoto ^{[9
]}

Hoshi, Namiko ^{[9
]}

Moriya, Kei ^{[10
]}

Tsuchiya, Kiichiro ^{[11
]}

Yamaguchi, Yoshiharu ^{[12
]}

Kunisaki, Reiko ^{[13
]}

Takahara, Masahiro ^{[14
]}

Takagi, Tomohisa ^{[15
]}

Takehara, Tetsuo ^{[16
]}

Hirai, Fumihito ^{[17
]}

Kakimoto, Kazuki ^{[18
]}

Esaki, Motohiro ^{[19
]}

Nakase, Hiroshi ^{[20
]}

Kinjo, Fukunori ^{[21
]}

Torisu, Takehiro ^{[22
]}

Kanmura, Shuji ^{[23
]}

Narimatsu, Kazuyuki ^{[24
]}

Matsuoka, Katsuyoshi ^{[25
]}

Hiraga, Hiroto ^{[26
]}

Yokoyama, Kaoru ^{[27
]}

Honzawa, Yusuke ^{[28
]}

Naganuma, Makoto ^{[28
]}

Saruta, Masayuki ^{[29
]}

Kodama, Yuzo ^{[9
]}

Chiba, Tsutomu ^{[30
]}

Seno, Hiroshi ^{[1
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan

[2] Kyorin Univ, Dept Gastroenterol & Hepatol, Sch Med, Mitaka, Tokyo 1818611, Japan

[3] Kyoto Univ, Grad Sch Med, Sect Clin Epidemiol, Dept Community Med, Kyoto 6068507, Japan

[4] Asahikawa Med Univ, Div Gastroenterol, Dept Internal Med, Asahikawa, Hokkaido 0788510, Japan

[5] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Tokyo 1138519, Japan

[6] Shiga Univ Med Sci, Dept Med, Otsu, Shiga 5202192, Japan

[7] Juntendo Univ, Dept Gastroenterol, Sch Med, Tokyo 1138421, Japan

[8] Fujita Hlth Univ, Dept Adv Endoscopy, Sch Med, Toyoake, Aichi 4701192, Japan

[9] Kobe Univ, Grad Sch Med, Div Gastroenterol, Dept Internal Med, Kobe, Hyogo 6500017, Japan

[10] Nara Prefecture Gen Med Ctr, Dept Gastroenterol, Nara 6308581, Japan

[11] Univ Tsukuba, Inst Med, Dept Gastroenterol, Tsukuba, Ibaraki 3058576, Japan

[12] Aichi Med Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Nagakute, Aichi 4801195, Japan

[13] Yokohama City Univ, Med Ctr, Inflammatory Bowel Dis Ctr, Yokohama, Kanagawa 2320024, Japan

[14] Okayama Univ, Grad Sch Med, Dept Gastroenterol & Hepatol Dent & Pharmaceut Sc, Okayama 7008558, Japan

[15] Kyoto Prefectural Univ Med, Dept Mol Gastroenterol & Hepatol, Kyoto 6028566, Japan

[16] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan

[17] Fukuoka Univ, Fac Med, Dept Gastroenterol, Fukuoka 8140180, Japan

[18] Osaka Med & Pharmaceut Univ, Dept Internal Med 2, Takatsuki, Osaka 5698686, Japan

[19] Saga Univ, Fac Med, Dept Internal Med, Div Gastroenterol, Saga 8498501, Japan

[20] Sapporo Med Univ, Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 0608543, Japan

[21] Urasoe Gen Hosp, Ctr Gastroenterol, Urasoe 9012102, Japan

[22] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 8128582, Japan

[23] Kagoshima Univ, Grad Sch Med & Dent Sci, Div Digest & Lifestyle Dis, Kagoshima 8908520, Japan

[24] Natl Def Med Coll, Dept Internal Med, Tokorozawa, Saitama 3598513, Japan

[25] Toho Univ, Sakura Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Sakura, Chiba 2858741, Japan

[26] Hirosaki Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Hirosaki, Aomori 0368563, Japan

[27] Kitasato Univ, Sch Med, Dept Gastroenterol, Sagamihara, Kanagawa 2520375, Japan

[28] Kansai Med Univ, Dept Internal Med 3, Div Gastroenterol & Hepatol, Osaka 5731010, Japan

[29] Jikei Univ, Sch Med, Dept Gastroenterol & Hepatol, Div Internal Med, Tokyo 1058471, Japan

[30] Kansai Elect Power Hosp, Dept Gastroenterol & Hepatol, Fukushima Ku, Osaka 5530003, Japan

来源：

JOURNAL OF GASTROENTEROLOGY | 2024年

关键词：

Anti-integrin alpha v beta 6 antibody; Ulcerative colitis; Colonic Crohn's disease; Diagnostic biomarker; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE;

D O I：

10.1007/s00535-024-02176-x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background A serum biomarker for diagnosing ulcerative colitis (UC) remains to be established. Although we recently reported an anti-integrin alpha v beta 6 antibody (V6 Ab) for diagnosing UC with high sensitivity and specificity, no large-scale validation study exists. This study aimed to validate the diagnostic value of V6 Ab for UC using a nationwide multicenter cohort study. MethodsWe measured V6 Ab titers in patients definitively diagnosed with UC, Crohn's disease (CD), or other gastrointestinal disorders (OGDs). The primary outcome was the diagnostic value of V6 Ab. Secondary outcomes were factors associated with false-negative results in patients with UC and false-positive results in patients without UC and the heterogeneity of the diagnostic value of V6 Ab among the participating facilities. ResultsWe enrolled 1241, 796, and 206 patients with UC, CD, and OGD, respectively, from 28 Japanese high-volume referral centers. The diagnostic sensitivity of V6 Ab for UC was 87.7%, and its specificities for CD and OGDs were 82.0% and 87.4%, respectively. Multivariable logistic regression analysis showed that false-negative results were associated with older age at the time of sample collection, current smokers, lower partial Mayo score, and not receiving advanced therapies in patients with UC, and false-positive results were associated with colonic CD in patients with CD. No factor was associated with false-positive results in patients with OGDs. There were no significant differences in the diagnostic value of V6 Ab among the centers. ConclusionsThe diagnostic value of V6 Ab for UC was validated in the large-scale nationwide multicenter study.

引用

页码：86 / 95

页数：10

共 28 条

[21] Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
Danese, Silvio
Klopocka, Maria
Scherl, Ellen J.
Romatowski, Jacek
Allegretti, Jessica R.
Peeva, Elena
Vincent, Michael S.
Schoenbeck, Uwe
Ye, Zhan
Hassan-Zahraee, Mina
Rath, Natalie
Li, Gang
Neelakantan, Srividya
Banfield, Christopher
Lepsy, Christopher
Chandra, Deepa E.
Hung, Kenneth E.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (11) : 2324 - +
[22] Sustained effect of leukocytapheresis/granulocytapheresis versus anti-human TNF-α monoclonal antibody on ulcerative colitis: A 2-year retrospective study
Sakai, Masahiro
Hayashi, Koichi
Ito, Tomoyuki
Otani, Haruka
Mori, Yuya
Ito, Shinsuke
Endo, Keita
Matsuda, Hiroto
Yoshino, Kaede
Kitamura, Koichi
Kubota, Eiji
Motomura, Yasuaki
Suzuki, Yasuhiro
Fujitani, Shigeki
Suzuki, Toshihiko
MEDICINE, 2023, 102 (16) : E33368
[23] Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
Reinisch, Walter
Sandborn, William J.
Danese, Silvio
Hebuterne, Xavier
Klopocka, Maria
Tarabar, Dino
Vanasek, Tomas
Gregus, Milos
Hellstern, Paul A.
Kim, Joo Sung
Sparrow, Miles P.
Gorelick, Kenneth J.
Hoy, Michael
Goetsch, Martina
Bliss, Caleb
Gupta, Charu
Cataldi, Fabio
Vermeire, Severine
JOURNAL OF CROHNS & COLITIS, 2021, 15 (06) : 938 - 949
[24] Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis
Kierkus, Jaroslaw
Pesegova, Marina
Klopocka, Maria
Brankovic, Marija
Kasai, Noriyuki
Efuni, Sergey
Kong, Jennifer
Nakajima, Yu
Jordan, Christina
Matsui, Takeshi
Feagan, Brian G.
Strout, Vincent
CROHNS & COLITIS 360, 2020, 2 (03) : 1 - 10
[25] The impact of anti-TNFα therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015
Lund, Ken
Larsen, Michael Due
Knudsen, Torben
Kjeldsen, Jens
Nielsen, Rasmus Gaardskjaer
Norgard, Bente Mertz
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (10) : 1077 - 1085
[26] Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study
Ordas, I.
Domenech, E.
Manosa, M.
Garcia-Sanchez, V.
Iglesias-Flores, E.
Penalva, M.
Canas-Ventura, A.
Merino, O.
Fernandez-Banares, F.
Gomollon, F.
Vera, M.
Gutierrez, A.
Garcia-Planella, E.
Chaparro, M.
Aguas, M.
Gento, E.
Munoz, F.
Aguirresarobe, M.
Munoz, C.
Fernandez, L.
Calvet, X.
Jimenez, C. E.
Montoro, M. A.
Mir, A.
De Castro, M. L.
Garcia-Sepulcre, M. F.
Bermejo, F.
Panes, J.
Esteve, M.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (11) : 1709 - 1718
[27] Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis
Sandborn, W. J.
Bhandari, B. R.
Fogel, R.
Onken, J.
Yen, E.
Zhao, X.
Jiang, Z.
Ge, D.
Xin, Y.
Ye, Z.
French, D.
Silverman, J. A.
Kanwar, B.
Subramanian, G. M.
McHutchison, J. G.
Lee, S. D.
Shackelton, L. M.
Pai, R. K.
Levesque, B. G.
Feagan, B. G.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (02) : 157 - 169
[28] Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study
Suzuki, Kenji
Sameshima, Yukinori
Yokoyama, Junji
Terai, Shuji
Yoneyama, Hiroyuki
Atreya, Raja
Neurath, Markus F.
Hibi, Toshifumi
Asakura, Hitoshi
INFLAMMATION AND REGENERATION, 2024, 44 (01)

← 1 2 3 →